Petros Perros1, Miloš Žarković2, Claudio Azzolini3, Göksun Ayvaz4, Lelio Baldeschi5, Luigi Bartalena6, Antonella Boschi5, Claire Bournaud7, Thomas Heiberg Brix8, Danila Covelli9, Slavica Ćirić2, Chantal Daumerie10, Anja Eckstein11, Nicole Fichter12, Dagmar Führer13, Laszlo Hegedüs8, George J Kahaly14, Onur Konuk15, Jürg Lareida12, John Lazarus16, Marenza Leo17, Lemonia Mathiopoulou18, Francesca Menconi17, Daniel Morris19, Onyebuchi Okosieme16, Jaques Orgiazzi20, Susanne Pitz21, Mario Salvi9, Cristina Vardanian-Vartin22, Wilmar Wiersinga23, Martine Bernard24, Lucy Clarke25, Nicola Currò26, Colin Dayan16, Jane Dickinson25, Miroslav Knežević27, Carol Lane19, Claudio Marcocci17, Michele Marinò17, Lars Möller13, Marco Nardi28, Christopher Neoh25, Simon Pearce1, George von Arx12, Fosun Baloş Törüner4. 1. Department of Endocrinology, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. 2. Department of Endocrinology, School of Medicine, University of Belgrade, Belgrade, Serbia. 3. Department of Surgical and Morphological Sciences, Section of Ophthalmology, School of Medicine, University of Insubria, Varese, Italy. 4. Department of Endocrinology and Metabolism, Faculty of Medicine, Gazi University, Ankara, Turkey. 5. Department of Ophthalmology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 6. Endocrine Unit, Ospedale di Circolo, University of Insubria, Varese, Italy. 7. Department of Endocrinology and Nuclear Medicine, GHE-Hospices Civils de Lyon and Lyon 1 University, Lyon, France. 8. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark. 9. Graves' Orbitopathy Unit, Department of Clinical Sciences and Community Health, Fondazione Ca'Granda IRCCS, University of Milan, Milan, Italy. 10. Department of Endocrinology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 11. Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany. 12. Department of Ophthalmology, Interdisciplinary Centre for Graves' Orbitopathy, Olten, Switzerland. 13. Department of Endocrinology and Metabolism, University of Duisburg-Essen, Essen, Germany. 14. Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany. 15. Department of Ophthalmology, Faculty of Medicine, Gazi University, Ankara, Turkey. 16. Department of Endocrinology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK. 17. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 18. Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 19. Cardiff Eye Unit, University Hospital of Wales, Cardiff, UK. 20. Department of Endocrinology, Centre Hospitalier Lyon-Sud, Lyon, France. 21. Department of Ophthalmology, Johannes Gutenberg University Medical Center, Mainz, Germany. 22. Unité de Neuro-ophtalmologie, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France. 23. Department of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands. 24. Neuro-Ophthalmology Outpatient Clinics, GHE-Hospices Civils de Lyon and Lyon 1 University, Lyon, France. 25. Department of Ophthalmology, Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 26. Department of Ophthalmology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 27. Department of Ophthalmology, Medical School, Clinic for Ophthalmology, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia. 28. Dipartimento di Patologia Chirurgica Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy.
Abstract
BACKGROUND/AIMS: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time. METHODS: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000. RESULTS: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 (p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01). CONCLUSIONS: These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND/AIMS: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time. METHODS: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000. RESULTS: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 (p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01). CONCLUSIONS: These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Annika S Quinn; Leticia R Dujardin; Bridget Knight; James Benzimra; Anthony G Quinn; Bijay Vaidya Journal: Int Ophthalmol Date: 2017-02-08 Impact factor: 2.031
Authors: Peter N Taylor; Diana Albrecht; Anna Scholz; Gala Gutierrez-Buey; John H Lazarus; Colin M Dayan; Onyebuchi E Okosieme Journal: Nat Rev Endocrinol Date: 2018-03-23 Impact factor: 43.330
Authors: L Bartalena; G Veronesi; G E Krassas; W M Wiersinga; C Marcocci; M Marinò; M Salvi; C Daumerie; C Bournaud; M Stahl; L Sassi; C Azzolini; K G Boboridis; M P Mourits; M R Soeters; L Baldeschi; M Nardi; N Currò; A Boschi; M Bernard; G von Arx; P Perros; G J Kahaly Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256
Authors: Peter N Taylor; Lei Zhang; George J Kahaly; Marian Ludgate; Richard W J Lee; Ilaria Muller; Daniel G Ezra; Colin M Dayan Journal: Nat Rev Endocrinol Date: 2019-12-30 Impact factor: 43.330